- authorisedHuman Pharmacology (Phase I)- First administration to humans
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors (FiREBOLT)
The FiREBOLT study is testing a new cancer medicine, LY4337713, for the first time in humans. It is for adults with certain solid tumours—such as breast, bowel, or stomach cancer—that carry a protein called FAP. The main goal is to check its safety and find the right dose.
Germany · Netherlands - active not recruitingPHASE2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
This study looks at a new combination of experimental drugs, disitamab vedotin and tucatinib, for advanced breast or stomach cancers that have a specific marker called HER2. It aims to see how safe and effective this treatment is, and what side effects it might cause.
United States · Australia · Canada - recruitingPHASE1, PHASE2
HTL0039732 in Participants With Advanced Solid Tumours
This study is testing a new drug, HTL0039732, alone and with another cancer medicine, atezolizumab. It's for people with advanced solid tumours, aiming to see if blocking certain signals can help the immune system fight cancer. The goal is to find the right dose and see how well it works.
United Kingdom - recruitingPHASE1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This study is testing a new drug called sigvotatug vedotin for people with several types of advanced cancer. Researchers want to see if it's safe, what side effects it causes, and if it can help treat cancer, sometimes in combination with other common cancer medicines.
United States · France · South Korea - recruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
United States · Canada · China